logo
  Join        Login             Stock Quote

Hyperion's (HPTX) Ravicti Wins FDA Approval To Treat UCDs

 February 01, 2013 12:36 PM


(By Balachander) Hyperion Therapeutics Inc.'s (NASDAQ: HPTX) new drug to treat urea cycle disorders (UCDs) has won approval from the U.S. health regulators.

The U.S. Food and Drug Administration (FDA) cleared Ravicti (glycerol phenylbutyrate) for the chronic management of some UCDs in patients ages 2 years and older.

UCDs are genetic disorders that involve deficiencies of specific enzymes involved in the urea cycle, a series of biochemical steps normally required to remove ammonia from the blood.

Ravicti also was granted orphan product designation because it is intended to treat a rare disease, the FDA said.

According to the FDA, a major study showed Ravicti was as effective as Buphenyl - another drug approved to control UCDs - in controlling ammonia levels.

The most common side effects in patients treated with Ravicti include diarrhea, flatulence and headache.

The South San Francisco, California-based company is focused on developing therapeutics for orphan diseases and hepatology.

The stock, which has been trading in the 52-week range of $9.95 to $16.34, traded 3.20 percent higher at $16.13 on Friday.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageOil Prices Stubbornly Resilient Around $50 a Barrel.

The majority opinion seems to be that oil prices will drop further, popular targets being $30 and $40, with read on...

article imageADP: US February Payrolls Continue To Grow, But At Slower Rate

Payrolls at US companies posted another respectable gain in February, advancing 212,000 over the previous read on...

article imageAre You Prepared For Negative Interest Rates?

Last Tuesday, all eyes were on Federal Reserve Chief Janet Yellen. In prepared testimony, she offered a few read on...

article imageGreek Problems Born from Socialism

Our weekly commentaries provide Euro Pacific Capital's latest thinking on developments in the global read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center

Related Articles:

Recent Articles by Balachander
More Articles on: Medical



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.